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Background: The SLUG transcription factor has been linked with the KIT signalling pathway that is important for gastrointestinal
stromal tumour (GIST) tumourigenesis. Its clinical significance in GIST is unknown.
Methods: Influence of SLUG expression on cell proliferation and viability were investigated in GIST48 and GIST882 cell lines. The
association between tumour SLUG expression in immunohistochemistry and recurrence-free survival (RFS) was studied in two
clinical GIST series, one with 187 patients treated with surgery alone, and another one with 313 patients treated with surgery and
adjuvant imatinib.
Results: SLUG downregulation inhibited cell proliferation, induced cell death in both cell lines, and sensitised GIST882 cells to
lower imatinib concentrations. SLUG was expressed in 125 (25.0%) of the 500 clinical GISTs evaluated, and expression was
associated with several factors linked with unfavourable prognosis. SLUG expression was associated with unfavourable RFS both
when patients were treated with surgery alone (HR¼ 3.40, 95% CI¼ 1.67–6.89, P¼ 0.001) and when treated with surgery plus
adjuvant imatinib (HR¼ 1.83, 95% CI¼ 1.29–2.60, P¼ 0.001).
Conclusions: GIST patients with high tumour SLUG expression have unfavourable RFS. SLUG may mediate pro-survival signalling
in GISTs.
Gastrointestinal stromal tumour (GIST) is one of the most common
types of sarcoma (Ducimetiere et al, 2011). Approximately 90% of
GISTs contain an activating mutation either in KIT or PDGFRA
(platelet-derived growth factor receptor alpha) genes, which leads to
ligand independent activation of these receptor tyrosine kinases
(Hirota et al, 1998; Heinrich et al, 2003). GISTs that do not harbor a
KIT or PDGFRA mutation may have mutation in other genes, such
as succinate dehydrogenase (SDH) or neurofibromatosis type 1
(NF1; Nannini et al, 2014). Imatinib mesylate that targets KIT and
PDGFRA is the standard first-line therapy for patients with
metastatic GIST (Demetri et al, 2002), and the standard adjuvant
therapy for those patients whose tumour is considered to have a
*Correspondence: Dr H Sihto; E-mail: harri.sihto@helsinki.fi
Received 18 January 2017; revised 24 February 2017; accepted 3 March 2017;
published online 23 March 2017
r The Author(s) named above
FULL PAPER
Keywords: gastrointestinal stromal tumour; SLUG; SNAI2; survival; proliferation; apoptosis
British Journal of Cancer (2017) 116, 1195–1202 | doi: 10.1038/bjc.2017.82
Published by Springer Nature on behalf of Cancer Research UK. 1195
high risk for recurrence after surgery and contains an imatinib-
sensitive mutation (Dematteo et al, 2009; Joensuu et al, 2012a).
However, drug resistance frequently emerges when patients with
advanced GIST are treated with imatinib or other tyrosine kinase
inhibitors (Heinrich et al, 2006).
SLUG (the protein product of SNAI2) is a member of the Snail
family of zinc-finger transcription factors (Nieto, 2002). It is
involved in the regulation of cell migration during embryogenesis
and in tumour cell invasion and migration (Cobaleda et al, 2007).
SNAIL (product of SNAI1) and SLUG are expressed in several
types of human cancer, and their expression is often associated
with low-histological grade of differentiation, tumour recurrence,
metastasis and poor prognosis (Cobaleda et al, 2007; Wang et al,
2013). Although SNAIL and SLUG may induce the epithelial-
mesenchymal transition, they have a role also in the maintenance
of the stem cell-like properties of tumour cells. The stem cell-like
phenotype of tumour cells has been linked with resistance to
radiotherapy and chemotherapy in various types of cancer (Perez-
Losada et al, 2003; Catalano et al, 2004; Kurrey et al, 2009; Zhou
et al, 2014). Downregulation of SLUG inhibits proliferation of cell
lines derived from colorectal cancer, prostate cancer and
esophageal cancer, and, in accordance with this, overexpression
of SLUG increases proliferation of human glioblastoma cells
(Emadi Baygi et al, 2010; Yang et al, 2010; Zhang et al, 2011b; Qian
et al, 2013). SLUG is involved in cell survival also through either
direct or indirect transcriptional regulation of proapoptotic and
antiapoptotic genes (Tribulo et al, 2004; Wu et al, 2005; Bermejo-
Rodriguez et al, 2006; Vitali et al, 2008; Kim et al, 2014).
The stem cell factor (SCF, the ligand of KIT) and KIT signalling
upregulate SLUG in malignant mesothelioma cells (Catalano et al,
2004), and a few other studies have suggested a relationship
between SCF/KIT signalling and SLUG. Defects in SLUG and KIT
signalling lead to phenotypes with similar features both in humans
and in mice. Homozygous deletions of the SLUG gene in the
human cause the Waardenburg disease, a rare disorder associated
with abnormal pigmentation and sensorineural deafness (Sanchez-
Martin et al, 2003). Similarly, dysfunctional KIT may cause
piepaldism and sensorineural deafness (Spritz and Beighton, 1998).
Mice with targeted SLUG deletions have phenotypic similarities
with mice with defective KIT or SCF, including abnormal
pigmentation, and gonadal and haematopoietic defects (Motro
et al, 1991; Perez-Losada et al, 2002).
Because SLUG defects result in clinical phenotypes resembling
those that result from KIT defects, and SLUG influences cancer cell
proliferation and therapy resistance in various tumour types, we
investigated whether SLUG influences also GIST cell proliferation
and whether SLUG expression might be associated with the
histopathological and clinical properties of GISTs and patient
survival.
MATERIALS AND METHODS
Patients and tumour samples. The associations between GIST
SLUG expression, tumour features and patient survival outcomes
were investigated in two clinical series consisting of GIST patients.
The first series is a population-based cohort consisting of patients
who were treated with surgery in western Sweden in 1983–2000, as
described in detail in (Nilsson et al, 2005a). Out of the total of 288
patients in the cohort, we included in the current study 187
(64.9%) patients who had tumour tissue available, tumour
histology was compatible with GIST and stained positively for
KIT in immunohistochemistry, and provided that the patients had
information about gender, tumour diameter, and follow-up
available, whereas the remaining 101 (35.1%) patients were
excluded. None of the patients was treated with imatinib or other
tyrosine kinase inhibitors after surgery for GIST. The median
follow-up time of the patients was 44 months after surgery.
The second series consists of GIST patients who were entered to
the Scandinavian Sarcoma Group (SSG) XVIII/Arbeitsgemeinschaft
Internistische Onkologie (AIO) trial (Joensuu et al, 2012a, 2016).
SSGXVIII/AIO is an open-label, multicenter, phase 3 study. Patients
who had KIT-positive, operable tumour and who were at a high risk
for recurrence according to the modified National Institute of Health
(NIH) Criteria (Joensuu, 2008) were eligible. After macroscopically
complete surgery the patients were randomly allocated to receive
adjuvant imatinib 400mg per day orally either for 12 or 36 months.
A total of 400 patients from Finland, Germany, Norway and Sweden
were entered to the trial between February 2004 and September
2008. Representative tumour tissue for the current study was
available from 313 (85.1%) out of the 368 patients who provided
consent, had KIT-positive GIST in central histopathology review of
tumour tissue, and had localized disease at the time of randomisa-
tion. The median follow-up time after the date of randomisation was
6.1 years (Joensuu et al, 2016).
Institutional review committees of the Helsinki University
Hospital, Helsinki, Finland, and Sahlgrenska University Hospital,
Gothenburg, Sweden, approved the current study. The patients
who participated in the SSGXVIII/AIO trial provided written
informed consent for the study.
Immunohistochemistry and mutation analysis. Tissue micro-
arrays were constructed from representative parts of the formalin-
fixed paraffin-embedded tumour tissues using either a 0.7mm
diameter needle (the western Sweden series) or a 1mm diameter
needle (the SSGXVIII/AIO series). SLUG expression was evaluated
using immunohistochemistry in 5 mm thick tissue microarray
sections. Before staining, endogenous peroxidase activity was
blocked by incubating deparaffinized tissue in hydrogen perox-
idase, and antigen retrieval was performed using sodium citrate
(10mmol l 1, pH 6.0) in an autoclave (at 120 1C for 2min). The
anti-SLUG antibody (dilution 1 : 50; clone C19G7, Cell Signaling
Technology, Danvers, MA, USA) was diluted in a Normal antibody
Diluent (Immunologic, Duiven, The Netherlands), and incubated
on slides at þ 4 1C overnight. Binding of the primary antibody was
detected and visualized by using the N-Histofine Simple Stain
MAX PO (R) kit (Nichirei Biosciences Inc, Tokyo, Japan) and 3,30-
diaminobenzidine (ImmPACT DAB, Vector Laboratories, Burlin-
game, CA, USA) following the manufacturer’s recommendations.
The slides were counterstained with Mayers´ hematoxylin. Histo-
logically normal kidney tubule cells served as a positive control and
kidney glomerular cells as a negative control for the staining. The
samples were considered positive for SLUG expression when
nuclear and/or cytoplasmic staining was present in 420% of the
tumour cells. The immunostainings were analysed blinded without
knowledge of the clinical or histopathological data. KIT-positivity
and mutation status of the GIST samples was verified by
immunohistochemistry (rabbit polyclonal CD117-antibody, code
A4502, Dako, Glostrup, Denmark) and using PCR and bidirec-
tional sequencing as described elsewhere (Nilsson et al, 2005b;
Andersson et al, 2006; Wardelmann et al, 2006).
Cell lines and transfection. Two human GIST cell lines were
kindly provided by Dr Jonathan A Fletcher (Harvard Medical
School, Boston, Massachusetts, USA). GIST882 harbors a
homozygous missense mutation in KIT exon 13 encoding a
Lys642Glu (K642E) mutant oncoprotein (Tuveson et al, 2001).
GIST48 was obtained from a patient whose GIST progressed on
imatinib therapy, and harbors a KIT exon 11 V560D missense
mutation leading to p.Val560Asp and a secondary exon 17
(kinase activation loop) missense mutation D820A leading to
p.Asp820Ala (Bauer et al, 2006). The authenticity of the cell
lines was confirmed by sequencing. Cells were cultured in a
humidified 5% CO2 atmosphere at 37 1C in the RPMI 1640
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medium (GIBCO, CA, USA), supplemented with 20% fetal
bovine serum with 2% penicillin/streptomycin (GIBCO).
GIST882 and GIST48 cells were transfected using the
Lipofectamine 2000 Transfection Reagent (Invitrogen, Carlsbad,
CA, USA). The cells were serum starved for 6 h before transfection
in an Opti-MEM Reduced Serum Medium (GIBCO). The
transfections were done according to the manufacturer’s instruc-
tions adding 5 pM of siRNAs onto the cells. Transfections were
done with an ON-TARGET plus Human KIT siRNA and an ON-
TARGET plus Human SNAI2 (SLUG) siRNAs, which are pools of
target-specific siRNAs (Thermo Scientific Dharmacon, Rockford,
IL, USA). The ON-Target plus Non-Targeting Pool (Thermo
Scientific Dharmacon) was used as a negative control. Imatinib
mesylate was purchased from Cayman chemicals (Ann Arbor, MI,
USA).
Cell proliferation and cell death assays. GIST cell proliferation
was studied with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) assay (Roche Diagnostics, Indianapolis,
IN, USA). For the assay, GIST882 cells were plated at a density of
10 000 cells per well and GIST48 cells at a density of 15 000 cells
per well in 96-well plates. The assays were performed thrice, using
eight replicate wells at each time point. Cell proliferation was
analysed after adding 10 ml of the MTT reagent into each well and
incubation at 37 1C for 4 h, after which the solubilization solution
was added and the cells were incubated at 37 1C overnight. The
plates were analysed with a Multiscan EX Microplate photometer
(Thermo Scientific, Rockford, IL, USA) at the wavelength of
540 nm.
GIST cell death after exposure to KIT siRNA or SLUG siRNA
was analysed with a Click-iT TUNEL Alexa Fluor 488 Imaging
Assay (Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. GIST882 cells were plated at a density of
10 000 cells per well and GIST48 cells at a density of 15 000 cells
per well in 96-well plates. After 24 h of culture at 37 1C the cells
were transfected with siRNAs as described above. The TUNEL
assay was performed 96 h after siRNA transfections. Cells were
photographed (magnification 200) using an immunofluores-
cence microscope (Leica CTR6000, Leica microsystems, Bannock-
burn, IL, USA). Cell death was measured in three separate
experiments by counting the cells within 21 (5, 8 and 8)
photographed fields of the microscope. The frequency of dying
cells was expressed as the average number of dying cells per one
microscope field.
Western blotting. Cultured GIST882 and GIST48 cells were
rinsed in PBS (Lonza, Walkersville, MD, USA) and scraped into a
RIPA lysis buffer (Pierce Biotechnology, Rockford, IL, USA)
containing a Pierce Protease and Phosphatase Inhibitor Tablet
(Thermo Fisher Scientific Inc., Rockford, IL, USA), followed by
sonication. Protein concentration was determined with the Pierce
BCA Protein Assay Kit (Thermo Fisher Scientific Inc.). Protein
10 mg of protein was separated using a gel electrophoresis and
blotted onto an Immobilon-P Transfer Membrane (Millipore,
Billerica, MA, USA), and stained with a polyclonal rabbit anti-c-
KIT antibody (dilution 1 : 10000; clone A4502, Agilent Technol-
ogies Dako, Glostrup, Denmark), a polyclonal rabbit anti-SLUG
antibody (dilution 1 : 1000; clone C19G7, Cell Signaling Technol-
ogy), a polyclonal rabbit anti-b-actin antibody (dilution 1 : 10 000;
Bethyl Laboratories, Montgomery, TX, USA) or a Apoptosis
Western Blot Cocktail (Abcam, Cambridge, UK). Primary
antibodies were detected with specific horseradish-labelled sec-
ondary antibodies and using the SuperSignal West Pico and Femto
Chemiluminescent Substrate (Thermo Fisher Scientific Inc.),
following manufacturer’s instructions. The basal level of SLUG
expression was significantly lower in GIST882 cells than in GIST48
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Figure 1. SLUG expression in GIST, and association with recurrence-free survival. An example of negative (A) and positive (B) expression of SLUG
in GIST (magnification 200). Association of tumour SLUG expression with recurrence-free survival in the western Sweden population-based
series (C), and in the SSGXVIII/AIO series (D).
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cells. Protein expression was detected after diluting Femto
Substrate 1 : 5 with Pico Substrate.
Statistical analysis. The frequency tables were analysed with the w2
test or Fisher’s exact test. The groups resulting from the TUNEL
analysis were compared using the Mann–Whitney U-test. Cumula-
tive survival was estimated with the Kaplan–Meier method, and
survival between groups was compared using a univariable Cox
proportional hazards model. The interaction between tumour SLUG
expression and imatinib treatment in the SSGXVIII/AIO series was
calculated using a Gaussian process model for conditional event
probabilities. Gaussian process model can model nonlinear effects of
the covariates and interactions between covariates, and thus allow
inspection of whether SLUG has an interaction effect with imatinib
treatment or other covariates (Joensuu et al, 2012b). Overall survival
was calculated from the date of surgery to the date of death,
censoring patients who were alive on the last follow-up date.
Recurrence-free survival (RFS) was calculated from the date of
randomisation to the date of GIST recurrence or to death, whenever
death preceded recurrence, censoring the patients alive on the date
of last follow-up. The P values are two-sided. The statistical
calculations were done using the IBM SPSS Statistics package v. 22.0,
or with GPstuff 4.6 (Vanhatalo et al, 2013).
RESULTS
Associations between SLUG and clinical, histopathological and
molecular features of GIST. SLUG expression was present in 39
(20.9%) out of the 187 GISTs examined from the western Sweden
series and in 86 (27.5%) out of the 313 GISTs in the SSGXVIII/AIO
series (Figure 1A and B). Thus, SLUG was expressed in 125
(25.0%) out of the 500 GISTs that were immunostained for SLUG.
The intracellular localisation of SLUG was analysed in the western
Sweden series. SLUG was usually expressed both in the nucleus
and the cytoplasm, and, therefore, any GIST SLUG expression,
regardless of the subcellular location, was considered in further
analyses.
In the western Sweden series, where the patients did not receive
adjuvant imatinib after surgery, SLUG expression was associated
with a large tumour size at the time of the diagnosis, epithelioid type
of tumour histology and nuclear pleomorphism, the presence of
tumour necrosis, a high tumour mitotic count and presence of
metastases at the time of GIST detection. No significant association
was found with gender, age at the time of the diagnosis, tumour
location in the gastrointestinal tract, or a high risk for recurrence
when GISTs were classified according to the National Institute of
Health Consensus stratification scheme (Fletcher et al, 2002)
(Table 1). In the SSGXVIII/AIO series, where the patients were
treated with surgery and adjuvant therapy and the patients had high-
risk GIST, tumour SLUG expression was significantly associated
with the presence of tumour rupture, whereas no association was
found with the gender, age at the time of the diagnosis, tumour site,
size or mitotic count, or the mutated gene (Table 2).
Associations with survival. Patients whose GIST expressed SLUG
had less favorable RFS than patients whose GIST did not express
SLUG in the western Sweden series (HR¼ 3.40, 95% CI¼ 1.67–
6.89, P¼ 0.001; Figure 1C). Similarly, overall survival of these
patients was less favorable (HR¼ 1.88, 95% CI¼ 1.20–2.93,
P¼ 0.006). When SLUG expression (positive vs negative) was
entered as a covariable into a Cox multivariable analysis together
with tumour mitotic count (p5 vs 45 mitosis/50 HPFs), tumour
site (non-gastric vs gastric), and tumour size (as a continuous
variable) using RFS as the endpoint, only tumour size (HR¼ 1.09,
95% CI¼ 1.03–1.15, P¼ 0.002) and mitotic count (HR¼ 10.64,
95% CI¼ 4.13–27.38, Po0.001) were significantly associated with
survival, whereas non-gastric tumour site (HR¼ 1.90, 95%
CI¼ 0.91–3.96, P40.089) and SLUG expression (HR¼ 1.55, 95%
CI¼ 0.66–3.67, P40.319) were not. Similarly, SLUG expression in
the high risk group associated with poor RFS (HR¼ 1.76, 95%
CI¼ 1.06–2.92, P¼ 0.029) but was not independent prognostic
factor in Cox multivariable analysis (data not shown). Tumour
rupture data were not available; the 20 patients who had distant
metastases at the time of the diagnosis and four patients whose
mitotic count was not available were excluded from the analysis.
In accordance with these observations, in the SSGXVIII/AIO
series patients with SLUG-positive tumour had inferior RFS as
compared to those whose GIST did not express SLUG (HR¼ 1.83,
95% CI 1.29–2.60; P¼ 0.001; Figure 1D; Supplementary Figure 1).
There was no significant interaction between tumour SLUG
expression and the duration of adjuvant imatinib treatment. GIST
SLUG expression was associated with poor RFS also in the subset
of patients with KIT exon 11 deletion or insertion-deletion
mutation (n¼ 136, the largest single genotypic subgroup, of which
42 930.9%) stained positively for SLUG; HR¼ 2.22, 95% CI 1.30–
3.80; P¼ 0.004), whereas SLUG expression was not significantly
Table 1. Associations between GIST SLUG expression and 10
clinicopathological factors in the western Sweden series
Factor
SLUG negative
n (%)
SLUG positive
n (%) P
Age
Median (range) 69 (35–92) 69 (30–85) 0.532
Gender
Female 76 (81.7) 17 (18.3) 0.388
Male 72 (76.6) 22 (23.4)
Tumour size (cm)
Median (range) 5.0 (0.5–33.0) 8.0 (1.0–35.0) 0.002
Tumour site
Gastric 82 (80.4) 20 (19.6) 0.645
non-gastric 66 (77.6) 19 (22.4)
Mitotic count
o2 81 (89.0) 10 (11.0) 0.002
2–5 36 (72.0) 14 (28.0)
6–10 15 (78.9) 4 (21.1)
410 12 (54.5) 10 (45.5)
N.A. 4 1
Histology
Epithelioid 11 (52.4) 10 (47.6) 0.001
Spindle-like 114 (86.4) 18 (13.6)
Mixed 19 (73.1) 7 (26.9)
N.A. 4 4
Metastases at the time of diagnosis
Present 12 (60.0) 8 (40.0) 0.039
Not present 136 (81.4) 31 (18.6)
Nuclear pleomorphism
No or minimal 40 (93.0) 3 (7.0) o0.0001
Moderate 87 (82.9) 18 (17.1)
Severe 17 (53.1) 15 (46.9)
N.A. 4 3
Tumour necrosis
Not present 76 (83.5) 15 (16.5) 0.003
Present 23 (59.0) 16 (41.0)
N.A. 49 8
Risk classification (NIH)a
Very low 28 (90.3) 3 (9.7) 0.217
Low 46 (80.7) 11 (19.3)
Intermediate 18 (90.0) 2 (10.0)
High 44 (74.6) 15 (25.4)
Abbreviations: N.A., not available; NIH, the National Institutes of Health.
aCancers with metastases at the time of the diagnosis (n¼ 20) were excluded from the
analysis.
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associated with RFS among patients with KIT exon 11 substitution
mutation (n¼ 59, the second largest genotypic subgroup, of which
14 [23.7%] had positive staining for SLUG; HR¼ 1.56, 95% CI
0.58–4.24; P¼ 0.379). Tumour SLUG expression was indepen-
dently associated with GIST patient RFS when it was entered into a
Cox multivariable analysis as a covariable together with the four
established prognostic factors in GIST (tumour mitotic count,
tumour site, tumour rupture and tumour size) and the duration of
adjuvant imatinib (1 year or 3 years) in the SSGXVIII/AIO series
(HR¼ 1.63, 96% CI 1.13.2.36, P¼ 0.009; Table 3). However, each
of the four standard factors and the duration of adjuvant imatinib
predicted GIST recurrence more strongly than tumour SLUG
expression (P¼ 0.001 or smaller for each covariable, Table 3). The
results of the Cox multivariable model were essentially similar and
tumour SLUG expression remained an independent factor when
tumour mitotic count was entered into the model categorised as
shown in Table 2 in place of a continuous covariable.
SLUG and KIT silencing in GIST cell lines. The effect of SLUG
silencing was investigated in the GIST48 and GIST882 cell lines.
Both cell lines expressed SLUG, but expression was substantially
weaker in GIST882 as compared with GIST48 (Figure 2A and B).
As tumour SLUG expression was associated with a high GIST cell
proliferation rate in the western Sweden series, we studied whether
SLUG promotes cell viability in GIST48 and GIST882 cell lines
using the MTT assay. Blocking of SLUG expression by RNA
interference reduced cell proliferation in both cell lines during six
days of culture (Po0.001 for each cell line, standard error (s.e.) in
all measured time pointso±0.01; Figure 2C and D). Down-
regulation of KIT or SLUG with siRNAs increased cell death in
both cell lines when the numbers of dying cells were measured
using the TUNEL assay 96 h after treatment with the siRNAs
(Figure 2E and F). In the GIST882 cell line SLUG siRNA
transfection increased the mean proportion of DNA fragmentation
in nuclei from 18.3% (s.e.¼±2.6%) in the control siRNA to 33.2%
(s.e.¼±5.1%, P¼ 0.029) and KIT siRNA to 35.4% (s.e.¼±5.3%,
P¼ 0.045). Similarly, in the GIST48 cell line the mean proportion
of dying cells increased from 10.7% (s.e.¼ 1.8%) in the control
to 28.4% (s.e.¼±4.2%, P¼ 0.008) and 34.7% (s.e.¼±4.0%,
P o0.001) after treating the cells with SLUG siRNA and KIT
siRNA, respectively. In addition, downregulation of SLUG showed
synergy with imatinib on GIST882 cell line proliferation and
sensitised cells to imatinib-induced apoptosis as measured with
presence of caspase cleaved PARP (Figure 2G and H), although
synergistic effect was not found in GIST48 cell line (data not
shown).
DISCUSSION
We found that tumour SLUG expression was present in a quarter
of GISTs and that its expression was associated with unfavourable
RFS both in a patient population treated with surgery alone and in
those treated with surgery and adjuvant imatinib. In line with the
adverse influence of SLUG expression on survival outcomes, SLUG
expression was associated with a few known risk factors for GIST
recurrence and metastasis, such as a high cell proliferation rate,
presence of tumour rupture, and presence of distant metastases at
the time of the diagnosis. However, tumour SLUG expression was
not associated with non-gastric location of the primary tumour,
which is considered an established adverse prognostic factor in
GIST (Joensuu et al, 2016). Blocking of SLUG expression using
siRNA reduced cell proliferation and increased cell death in vivo in
the two GIST cell lines investigated.
To our knowledge, this is the first report concerning the clinical
significance of SLUG expression in GIST. Prior studies, performed
in patient populations such as oesophageal cancer, colorectal
cancer and lung cancer, found that patients with SLUG-positive
cancer have poor outcomes also in these types of human cancer
(Uchikado et al, 2005; Shioiri et al, 2006; Wu et al, 2015). Taken
together, these observations suggest that tumour SLUG expression
may be an adverse prognostic feature in several types of human
cancer, including some sarcomas. In the present series, tumour
SLUG expression was a relatively strong adverse factor in
univariable survival analyses and had independent prognostic
value in a multivariable analysis of the SSGXVIII/AIO series. On
the other hand, a majority of even high-risk GISTs did not express
Table 2. Associations between GIST SLUG expression and 7
clinicopathological factors in the SSGXVIII/AIO series
Factor
SLUG negative
n (%)
SLUG positive
n (%)
P
Age
Median (range) 61.5 (26–75) 60 (22–83) 0.806
Gender
Female 113 (73.9) 40 (26.1) 0.606
Male 114 (71.3) 46 (28.8)
Tumour size—cm
Median (range) 9.7 (2.5–35.0) 9.0 (1.5–30.0) 0.930
Location
Gastric 127 (75.1) 42 (24.9) 0.228
Non-gastric 98 (69.0) 44 (31.0)
Mitotic count
o2 52 (82.5) 11 (17.5) 0.245
2–5 59 (71.1) 24 (28.9)
6–10 32 (72.7) 12 (27.3)
410 79 (68.7) 36 (31.3)
N.A. 5 3
Tumour rupture
No 187 (75.1) 62 (24.9) 0.044
Yes 40 (62.5) 24 (37.5)
Mutation site
KIT 176 (72.4) 67 (27.6)
Exon 9 17 5
Exon11 156 60
Exon 13 3 2
PDGFRA 25 (65.8) 13 (34.2)
Wild type for KIT
and PDGFRA
19 (79.2) 5 (20.8) 0.506
Abbreviations: HPF, high power field of a microscope; N.A., not available; PDGFRA,
platelet-derived growth factor receptor alpha gene.
Table 3. Influence of six factors on recurrence-free survival in
a Cox multivariable model in the SSGXVIII/AIO series
Variable Hazard ratio (95% CI) P
Tumour mitotic count 1.03 (1.02–1.03) o0.001
As a continuous variable
Tumour site 3.03 (2.05–4.46) o0.001
Non-gastric vs gastric
Duration of adjuvant imatinib 2.22 (1.52–3.22) o0.001
1 year vs 3 years
Tumour rupture 2.25 (1.52–3.33) o0.001
Present vs absent
Tumour size 1.05 (1.02–1.07) 0.001
As a continuous variable
Tumour SLUG expression 1.63 (1.13–2.36) 0.009
Present vs absent
Abbreviation: CI, confidence interval.
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SLUG suggesting that elevated SLUG expression is not related to
cancer progression.
To understand better the adverse effect of SLUG on GIST
patient outcome, we studied SLUG in the two GIST cell lines.
These cell lines had distinct basal SLUG expression levels, and
SLUG downregulation decreased cell viability and increased cell
death in both cell lines in accordance with studies performed in
other experimental tumour models (Wu et al, 2005; Vitali et al,
2008; Emadi Baygi et al, 2010). SLUG may antagonise apoptosis by
regulation of caspases or repressing expression of the pro-apoptotic
PUMA protein (Tribulo et al, 2004; Wu et al, 2005). However, we
did not find any effect on PUMA expression in GIST cell lines
when SLUG expression was repressed using siRNA (data not
shown). SLUG silencing sensitises cholangiocarcinoma and ovarian
cancer cells to cisplatin (Zhang et al, 2011a; Haslehurst et al, 2012),
and SLUG may have an essential role in a signalling network
that drives survival and imatinib resistance of Bcr-Abl-expressing
cells (Mancini et al, 2010). As a transcription factor, SLUG may
mediate cell survival and drug resistance in cancer cells by
regulation set of genes functioning in various signalling pathways.
Theoretically, imatinib mesylate and SLUG down-regulation could
be combined to treat some malignancies such as GIST (Vitali et al,
2008; Mancini et al, 2010), but the means to deliver effective
anti-SLUG therapy efficiently and safely are currently lacking.
It remains to be seen whether emerging technologies such as
the RNA silencing technology or target proteins to proteolysis
targeting chimeras (PROTACs) will resolve this problem
(Deshaies, 2015).
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Figure 2. SLUG and KIT siRNA silencing in GIST cell lines. An example of SLUG, KIT and actin expression after siRNA transfection in the GIST882
(A) and the GIST48 (B) cell line. Cell proliferation decreased (C, D) and the rate of cell death (E, F) increased in the GIST882 cell line and in the
GIST48 cell line after transfection with KIT or SLUG siRNA. An efficacy of imatinib in the GIST882 cell line was enhanced by the downregulation of
SLUG expression (G). The simultaneous downregulation of SLUG expression and KIT inhibition sensitised GIST882 cells to lower imatinib
concentration (H).
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SLUG expression was associated with unfavourable survival
outcomes in both series in univariable analyses, but it emerged as
an independent factor in the SSGXVIII/AIO trial series only. This
might suggest that SLUG is a predictive factor rather than a
prognostic factor in GIST, but such a conclusion might be
premature and requires confirmation from other series. The
patient populations differ between the series as the western Sweden
GIST series is a population-based series that includes both low-risk
and high-risk patients, whereas the SSGXVIII series included
patients with a high estimated risk for recurrence. The covariables
in the Cox models may also differ.
The present study has some limitations. The clinical series
investigated are large and the treatment given could be taken into
account in the analyses, but the quantitation of SLUG expression
from immunostained slides is somewhat subjective, and we could
not control factors that may influence SLUG detection by
immunohistochemistry, such as the methods and the times of
tissue fixation. SLUG expression or nuclear localisation in some
tumours might be missed from analysis of tissue microarray
samples, as SLUG expression may vary within tumour tissue.
However, we found significant differences in patient outcome
when only the nuclear expression or both the cytoplasmic and the
nuclear expression were considered in survival analyses (data not
shown). Finally, there are only few GIST cell lines available, and we
had access to only two of these despite our efforts to obtain more
cell lines for the study. Although the findings from the two cell
lines are supportive to the data from the clinical series, they should
be viewed with some caution, as the effects of SLUG might vary
between GISTs and the cell lines derived from them.
In sum, the results suggest that about a quarter of GISTs express
SLUG and that its expression is associated with unfavourable RFS
of GIST patients. The results suggest that SLUG may function as a
pro-survival factor in GIST.
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